At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed previously untreated bulky stage II or stage III or IV follicular non-Hodgkin's lymphoma, Grade I-III
- ✓CD20 antigen positive
- ✓Fewer than 5,000/mm³ circulating lymphoid cells on WBC differential
- ✓Bidimensionally measurable disease
- ✕Clinical evidence of CNS involvement by lymphoma
- ✕Impaired cardiac status including severe coronary artery disease, cardiomyopathy, congestive heart failure, or serious arrhythmia
- ✕Prior monoclonal antibodies for cancer
- ✕Prior chemotherapy for lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
In Brief
A Phase 3 clinical trial evaluating rituximab, cyclophosphamide, and 4 other interventions for Lymphoma. Completed, enrolled 571 participants across 259 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibodies given together with combination chemotherapy to see how well they work in treating patients with newly-diagnosed non-Hodgkin's lymphoma.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given orally
Given IV
Given IV